bluuebunny/crossref_metadata_2025_split huggingface dataset:
P1633Age, creatinine, and ejection fraction (ACEF) score continues to predictive prognosis in patients with ischemic cardiomyopathy
Authors: Chen W Z , Ran P , Cai A P 
Published: October 2019

Abstract

Purpose
ACEF (Age, Creatinine, and Ejection Fraction) andACEFMDRD (Modification of Diet in Renal Disease) score have been validated as effective predictors for prognosis in patients undergoing elective cardiac surgery or PCI. However, the predictive value for ICM (Ischemic Cardiomyopathy)was not clear. This study sought to investigate their predictive value in patients with ICM.

Methods
862 ICM patients hospitalized in the Department of Cardiology were prospectively enrolled during November 2014 and December 2017.Inclusion criteria: previous definite diagnosis of myocardial infarction, previous PCI, CABG, or coronary angiographic findings of one or more vessel stenosis >70%; Simpson echocardiography showed LVEF <45%. Exclusion criteria: malignant tumors of any organ or once had a history of malignancies; and other serious diseases with estimated survival time less than one year.The ACEF score was calculated by the formula: age/ejection fraction + 1 (if creatinine >176 μmol/L). As for ACEFMDRD score, estimated glomerular filtration rate (eGFR) was calculated using the MDRD formula. Then using the formula: age/EF +1 point for every 10 mL/min reduction in eGFRMDRD below 60 ml/min per 1.73 m2 (up to a maximum of 6 points). Patients were divided into low, middle and high ACEF, ACEFMDRD tertiles. The median duration of follow-up was 13 months (IQR: 7–23 months). The clinical endpoints were all-cause mortality, cardiac mortality, major adverse cardiovascular and cerebrovascular events (MACCEs) and re-hospitalization for heart failure (HF).

Results
The mean original ACEF and ACEFMDRD score were 1.99±0.63 and 2.53±1.42. Patients in high ACEF and ACEFMDRD tertile were associated with significantly higher all-cause and cardiac mortality, MACCEs and re-hospitalization for HF. Compared with ACEFMDRD score, original ACEF exhibited similar discrimination and predictive ability on all-cause mortality (AUC: 0.739 vs. 0.724, P=0.567), cardiac mortality (AUC: 0.733 vs. 0.717, P=0.525), MACCEs (AUC: 0.635 vs. 0.624, P=0.587) and rehospitalizaiotn (AUC: 0.642 vs. 0.632, P=0.757). In multivariate Cox analysis, the original ACEF or ACEFMDRD score were related with increasing risks of all-cause mortality (HR: 2.00 vs. 1.32, 95% CI: 1.46–2.73 vs. 1.13–1.53, P<0.001), cardiac mortality (HR: 1.97 vs. 1.28, 95% CI: 1.43–2.70 vs. 1.10–1.50, P<0.001 vs. P=0.002), MACCEs and re-hospitalization for HF, respectively.
ROC curves of cardiac mortality

Conclusions
In patients with ICM, the original ACEF and ACEFMDRD score are independent predictors of adverse outcomes during 13-month follow-up, respectively.

Acknowledgement/Funding
None
P1639Prognostic utility of H2FPEF score in heart failure with preserved ejection fraction
Authors: Przewlocka-Kosmala M , Marwick T H , Jankowska E A , Ponikowski P , Kosmala W 
Published: October 2019

Abstract

H2FPEF (obesity, atrial fibrillation, age >60 yrs, ≥2 antihypertensives, E/e' >9, and pulmonary artery systolic pressure by echo >35 mmHg) is a newly-developed score used for establishing the likelihood of heart failure with preserved ejection fraction (HFpEF). Given the clinical significance of its components, it is tempting to speculate that this algorithm might be useful for cardiovascular (CV) risk prediction.

Aim
To investigate the prognostic value of H2FPEF score in a well-characterized HFpEF population.

Methods and results
A group of 205 patients (64±8yrs) with symptomatic HFpEF, underwent clinical and echocardiographic evaluation. At a mean follow-up of 26.2 months, 64 patients (31%) experienced the composite of CV hospitalization or death, and 51 (25%) HF hospitalization. Cox regression analysis revealed that H2FPEF was significantly associated with both study endpoints (HR: 1.30; 95% CI: 1.10 to 1.54; p=0.002 for CV hospitalization or death, and 1.45; 95% CI: 1.21 to 1.75; p<0.001 for HF hospitalization). The prognostic value of H2FPEF was non-inferior to a traditional prognosticator in HF - MAGGIC (Meta-analysis Global Group in Chronic Heart Failure) risk score (area under ROC curve 0.62 for H2FPEF and 0.65 for MAGGIC, p=0.58, for the composite end-point, and 0.66 for both predictors, p=0.96, for HF hospitalization). Using an externally-derived cutpoint for H2FPEF of 5 (considered as the upper limit of the range corresponding to an intermediate probability of HFpEF), we demonstrated that the subset with the score equal to or above this threshold was characterized by a higher risk of both study end-points (Figure).
Figure 1. Kaplan-Meier estimates of survival free of the study outcomes according to H2FPEF score.

Conclusions
H2FPEF score, originally dedicated to discrimination of HFpEF, is a potent prognosticator in this condition, with the ability to identify increased clinical risk comparable to MAGGIC score.
P1649Prognostic significance of serum cholinesterase in patients with acute decompensated heart failure with preserved ejection fraction: insights from PURSUIT-HFpEF registry
Authors: Seo M , Yamada T , Tamaki S , Yasumura Y , Uematsu M , Abe H , Higuchi Y , Hikoso S , Nakatani D , Fukunami M , Sakata Y 
Published: October 2019

Abstract

Background
Comorbidities strongly influence the prognosis in heart failure with preserved ejection fraction (HFpEF). Malnutrition is one of the most important comorbidities among heart failure patients. Serum cholinesterase (CHE), one of the markers of malnutrition, was reported to be a prognostic factor in patients with chronic heart failure. In addition, we previously reported prognostic significance of CHE from a single center registry data of acute decompensated heart failure (ADHF). The aim of this study is to conduct external validation of the prognostic role of CHE using multi-center HFpEF registry.

Methods and results
Patients data were extracted from The Prospective mUlticenteR obServational stUdy of patIenTs with Heart Failure with Preserved Ejection Fraction (PURSUIT HFpEF) study. PURSUIT-HFpEF study is a prospective multicenter observational study in which collaborating hospitals in Osaka recorded clinical, echocardiographic, and outcome data of patients with ADHF and preserved ejection fraction. Between June 2016 and January 2018, 381 patients were enrolled and we excluded patients without sufficient laboratory data and in-hospital death. Finally, we analyzed 204 patients with survival discharge. Laboratory data including CHE and echocardiography were obtained just before discharge. The endpoint of this study is the composite of all-cause death and worsening heart failure re-admission (cardiac event). During a follow up period of 0.92±0.37 years, 49 patients had cardiac event. CHE was significantly lower in patients with than without cardiac event (183±67 vs 223±71 U/L, p<0.0001). At multivariate Cox analysis, CHE (p=0.0020) was significantly associated with cardiac event, independently of NT-pro BNP after adjustment of age, sex, eGFR and hemoglobin. ROC curve analysis showed that AUC of CHE for the prediction of cardiac event was 0.706 (95% CI 0.638–0.768). Kaplan-Meier analysis showed that patients with low CHE (<211U/L defined by median) had a significantly greater risk of cardiac event (35% vs 13% p=0.0002).
Figure 1

Conclusion
Serum cholinesterase level is the useful prognostic marker for the prediction of cardiac event in patients with ADHF with preserved ejection fraction.

Acknowledgement/Funding
Roche diagnostics, FUJIFILM Toyama Chemical
P1650Clinical significance of uNGAL, uKIM-1, and uL-FABP in patients with acute pulmonary edema
Authors: Kuragaichi T , Hotta K , Miyata A , Nakayama H , Nishimoto Y , Kobayashi T , Saga S , Fukuhara R , Yoshitani K , Taniguchi R , Toma M , Miyamoto T , Sato Y 
Published: October 2019

Abstract

Introduction
Novel urinary biomarkers such as urinary neutrophil gelatinase-associated lipocalin (u-NGAL),urinary kidney injury molecule-1 (u-KIM-1), and urinary liver-type fatty acid-binding protein (uL-FABP) are proposed to be reliable markers for acute heart failure (AHF). Acute pulmonary edema (APE) is one of the vascular phenotypes of AHF, such as `vascular failure”, often with high blood pressure at admission. We aimed to investigate the differences in the clinical impact and prognostic utility of urinary biomarkers in AHF patients with and without APE.

Methods and results
This prospective observational study included 203 AHF patients (mean age: 77 years, 52% male). uL-FABP, u-NGAL, and u-KIM-1 were measured at admission and before discharge, with correction for urinary creatinine. APE was defined as acute-onset dyspnea and radiographic alveolar edema requiring non-invasive positive pressure ventilation. The primary outcome was a composite of all-cause death and AHF rehospitalization for 1 year. The median uL-FABP levels at admission were higher in APE (n=42) than in non-APE patients (n=161; 10.8 [4.5–23.7] vs. 20.7 [5.9–63.5] μg/gCr, p=0.017), whereas u-KIM-1, u-NGAL, and serum creatinine did not significantly differ between AHF patients with and without APE. The primary outcome did not differ between patients with and without APE. However, among patients with APE, Kaplan–Meier analysis showed that higher uL-FABP (≥median: 20.7 μg/gCr) was associated with adverse events (log-rank: p=0.019). After adjusting for age, sex, serum creatinine, and brain natriuretic peptide, multivariable Cox hazard analysis showed that higher uL-FABP is an independent predictor of adverse events (HR: 4.0 [1.2–18.2], p=0.023).

Conclusion
Unlike u-NGAL and u-KIM-1, uL-FABP was higher in APE patients than in non-APE patients. Further, among patients with APE, higher uL-FABP was predictive for poor prognosis.

Acknowledgement/Funding
None
P1653Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure
Authors: Aimo A , Januzzi J , Mueller C , Miro' O , Pascual-Figal D A , Jacob J , Herrero-Puente P , Llorens P , Wussler D , Kozhuharov N , Sabti Z , Breidthardt T , Vergaro G , Passino C , Emdin M 
Published: October 2019

Abstract

Background
High-sensitivity troponin T (hs-TnT) reflects the severity of ongoing myocardial damage and holds independent prognostic significance in chronic heart failure (HF). In acute HF (AHF), its additive prognostic value over natriuretic peptides is unclear.

Methods
Individual data of 1571 AHF patients with admission hs-TnT were collected from 3 cohorts.

Results
Patients were aged 78±10 years, and 51% were men. Median hs-TnT and N-terminal fraction of pro-B-type natriuretic peptide (NT-proBNP) concentrations were 43 ng/L (interquartile interval 26–69) and 5660 (2693–12466), respectively. Patients experiencing in-hospital death (n=187, 13%) had significantly higher hs-TnT and NT-proBNP on admission (both p<0.001). The risk of in-hospital death increased by 45% per each doubling of hs-TnT (HR 1.45, 95% confidence interval - CI 1.31–1.59, p<0.001), and by 32% per each doubling of NT-proBNP (HR 1.32, 95% CI 1.17–1.50, p<0.001). Patients with hs-TnT ≥43 ng/L and NT-proBNP ≥5660 ng/L had a 2.7-fold higher risk of in-hospital death (relative risk - RR 2.7, 95% CI 1.7–4.5). Among the 1262 patients discharged, 1024 deaths occurred over a median 11-month follow-up (4–22). In a model including NT-proBNP, hs-TnT ≥43 ng/L was a strong, independent predictor of all-cause death at 6, 12 and 24 months, and the composite of cardiovascular death or HF hospitalization at 6 and 24 months. hs-TnT ≥43 ng/L also improved risk reclassification.

Conclusions
The risk of in-hospital death is almost 3 folds higher with admission hs-TnT ≥43 ng/L and NT-proBNP ≥5660 ng/L, and hs-TnT ≥43 ng/L holds strong independent prognostic significance for post-discharge outcome.
P1657Hyperuricaemia treatment in acute heart failure patients does not improve their long-term prognosis: a propensity score matched analysis from the AHEAD registry
Authors: Miklikova M , Jarkovsky J , Benesova K , Miklik R , Felsoci M , Spinar J , Dusek L , Parenica J 
Published: October 2019

Abstract

Background
Hyperuricaemia is associated with a poorer prognosis in heart failure (HF) patients. Benefits of hyperuricaemia treatment with allopurinol have not yet been confirmed in clinical practice. The aim of our work was to assess the benefit of allopurinol treatment in a large cohort of HF patients.

Methods and results
The prospective acute heart failure registry (AHEAD) was used to select 3,160 hospitalized patients with a known level of uric acid (UA) who were discharged in a stable condition. Hyperuricaemia was defined as UA ≥500μmol/l and/or allopurinol treatment at admission. The patients were classified into three groups: without hyperuricaemia, with treated hyperuricaemia and with untreated hyperuricaemia at discharge. Two- and five-year all-cause mortality were defined as endpoints. Patients without hyperuricaemia, unlike those with hyperuricaemia, had a higher left ventricular ejection fraction, a better renal function and higher haemoglobin levels, had less frequently diabetes mellitus and atrial fibrillation, and showed better tolerance to treatment with ACEIs/ARBs and/or beta-blockers. In a primary analysis, the patients without hyperuricaemia had the highest survival rate. After using the propensity score to set up comparable groups, the patients without hyperuricaemia had a similar five-year survival rate as those with untreated hyperuricaemia (42.0% vs 39.7%, p=0.362) whereas those with treated hyperuricaemia had a poorer prognosis (32.4% survival rate; p=0.006 vs non-hyperuricaemia group and p=0.073 vs untreated group).

Conclusion
Hyperuricaemia was associated with an unfavourable cardiovascular risk profile in HF patients. Treatment of hyperuricaemia with low doses of allopurinol did not improve the longterm prognosis of HF patients.

Acknowledgement/Funding
Ministry of Health CZ 65269705 and MUNI/A/1250/2017
P1686Natriuretic peptides personifying role in patients with arterial hypertension and chronic heart failure
Authors: Gubareva I , Gubareva E 
Published: October 2019

Abstract

Aim
The aim of research was to study NT-proBNP in patients with arterial hypertension (AH) and chronic heart failure (CHF).

Object and methods of research
420 male patients in age from 30 to 60 years old were examined: group 1 (n=180) – patients with AH without CHF, group 2 (n=86) – patients with AH and CHF, group 3 (n=74) – patients with CHF without AH and the group of control (n=80). NT-proBNP, fmol/ml, was measured.

Results
NT-proBNP had the highest levels in patients of group 3 in comparison with the group of control (p=0.046), group 1 (p=0.037) and group 2 (p=0.046). The duration of AH didn't affect the level of NT-proBNP (r=0.186; p=0.537). In the group with AH, the plasma level of NT-proBNP was lower in patients with 2 and 3 degrees of AH compared with patients with 1 degree of AH (p<0.05). In the group of patients with AH and CHF this pattern wasn't observed (p>0.05). NT-proBNP was interrelated with AH degree in group 1 (r=−0.624; p=0.023). Such a relationship wasn't established in group 2 (r=0.151; p=0.294), NT-proBNP was interrelated with NYHA functional class of CHF (r=0.215; p=0.049).
The diagnostic value of changes in the level of NT-proBNP in the diagnosis of grade 1 AH relative to 2–3 degrees of AH in patients without CHF: at the point of separation (cut off) 3.85 fmol/ml, sensitivity 83% and specificity of 71%. ROC-area under curve = 0.81. The quality of the model was very good. NT-proBNP determining diagnostic value analysis to predict the enhancement in NYHA functional class of CHF in patients with AH and CHF: at a separation point of 3.4 fmol/ml specificity of 71%, sensitivity – 76%. ROC-area under curve = 0.74.
We investigated the level of NT-proBNP in patients of groups 1 and 2 with different types of circadian blood pressure (BP) profiles. NT-proBNP levels were the highest in patients with “non-dipper”, “night-peaker” circadian blood pressure profile and differed significantly from patients profiles “dipper” and “over-dipper” as for systolic BP and for diastolic BP.
Data correlation analysis revealed the inverse relationship between NT-proBNP and SBP (r=−0.498; p=0.035). Since there were no patients with circadian profiles “night-peaker” and “over-dipper” in group 1, and the results of the study reflected the level of NT-proBNP in group 2, we studied the level of these hormones in patients with the same type of circadian profiles in group 1 and group 2. The level of NT-proBNP in patients of group 1 with “non-dipper” profile was reduced in comparison with patients of group 2 and “dipper” circadian profile.

Conclusion
Determination of natriuretic peptides in patients with AH and CHF personifies the diagnosis and prognosis of cardiovascular complications. Natriuretic peptides are involved in circadian blood pressure profile.
P1692Cardiac fibrosis in competitive triathletes is associated with arterial hypertension
Authors: Muench J , Knappe D , Witzel K , Von Stritzky A , Tahir E , Lund G , Patten M 
Published: October 2019

Abstract

Background
Myocardial fibrosis is an occasional finding in asymptomatic athletes.

Purpose
Evaluation of clinical conditions with possible impact on cardiac fibrosis in competitive triathletes.

Methods
Cardiac fibrosis in 61 male competitive triathletes (>10 hrs of training per week, mean 45 yrs) and 19 controls (mean 38 yrs), was quantified using late gadolinium enhancement (LGE) in cardiac magnet-resonance imaging (CMR). Physical examination, past medical history, and routine lab diagnosis were performed and baseline characteristics like blood pressure at rest (BP), body mass index (BMI), and echocardiographic parameters were measured. Triathletes were sub-divided into LGE positives vs. negatives.

Results
All individuals appeared healthy with no drug history of note and a normal cardiac function according to echocardiography. Focal non-ischaemic LGE was detected in 18 triathletes (5.2±4.5 g; 3.5±2.8 g/m2) and none of the controls. Compared to LGE negative triathletes, LGE positives showed significantly higher systolic BP and BMI (see Table). 67% of the LGE positives and only 14% of the LGE negative athletes showed first degree arterial hypertension and 56% of the LGE positives vs. 21% of the LGE negatives were formally overweight (BMI≥25 kg/m2). Controls had smaller left atrial volume indices than the triathletes, in line with characteristics of the athlete's heart. The triathletes were older than the controls (see Table below), but had a normal diastolic function. 38% of the controls and 31% of all triathletes were overweight. Equally to the LGE negatives, 14% of the controls were hypertensive.
Clinical parameters Athletes LGE+ LGE− Controls p-value (athletes vs. controls) p-value (LGE+ vs. LGE−) p-value (LGE− vs. controls) n 61 18 43 19 Age (yrs) 44.6±9.80 48.2±9.04 42.2±9.96 38.4±11.12 0.0371* 0.1222 0.0016* BMI (kg/m2) 24.1±2.57 25.3±2.75 23.8±2.4 24.5±2.74 0.2564 0.0315* 0.1228 Sys. BP (mmHg) 132±15.80 144±17.52 128±12.99 124±15.93 0.0145* 0.0020* 0.2426 LAVI (ml/m2) 29.13±6.79 31.45±8.02 26.68±6.26 24.25±5.48 0.0014* 0.4389 0.0053* All values shown as mean values with standard deviation, if not otherwise indicated, BMI = body mass index, LAVI = left atrial volume index, athletes = all triathletes; LGE+ = triathletes with cardiac LGE visualised by CMR, LGE− = triathletes without LGE in CMR. *Significant p-value, vs. = versus, Sys. BP = systolic blood pressure.

Conclusion
In competitive triathletes, there is a significant correlation between cardiac fibrosis and arterial hypertension at rest as well as overweight. We therefore recommend, that individuals with these characteristics should undergo cardiac consultation before starting endurance-training in competitive disciplines.
P1699Non-ST segment elevation miocardial infarction (NSTEMI) vs. Unstable angina (UA) in young women aged < 45 years - differences in symptomatology, clinical course, treatment and prognosis
Authors: Beckowski M , Gierlotka M , Polonski L , Gasior M , Dabrowski R , Zdrojewski T , Kowalik I , Drygas W , Szwed H 
Published: October 2019

Abstract

Background
Almost 50% of all ACS in young women are NSTEMI and UA. Due to the type of ACS we observed differences in the symptomatology, treatment and outcomes. The aim was to evaluate the differences in the clinical course and prognosis in young women aged ≤45 years with NSTEMI vs. UA.

Methods
We compared 1143 women aged ≤45y.o. with acute cardiac syndromes: 51% NSTEMI, 49% UA from the PL-ACS registry between 2007 - 2014.

Results
Chest pain was predominant in both group, with a higher incidence in NSTEMI group (91.7% vs. 84.7, p=0.0002). UA group was older (42y.o. vs. 41y.o p=0.003), more often presents atypical symptoms (8.0% vs. 1.5%, p<0,0001) mostly with dyspnea (3.9%vs. 1.7%, p=0.025). During NSTEMI more often occurred pre-hospital cardiac arrest (2.9% vs. 0.8%, p=0.0031). There was no difference between groups in general condition at admission expressed by Killip class. Onset-to-intervention time was longer in UA group (41.8 vs. 30.3 hour p=0.0053) resulted from longer door-to-intervention time only (3.3 vs. 1.5 hour, p<0.0001). In NSTEMI group more often the culprit artery was circumflex (17.1% vs. 9.3% p=0.0004) and diagonal branch (4.4% vs. 1.5%, p=0.0095) with a higher number of total occlusions (pre-procedural TIMI 0: 27.8% vs. 15.6% p=0,0023). Number of PCI was also higher in this group (50.9% vs. 36.1%, p<0.0001) without differences in completed revascularizations. In UA group in stent restenosis was found more often (2.8% vs. 1.5%, p=0.026). Drug eluting stents (DES) were often used in UA group (60.2% vs. 49.6% p=0.027). There were no difference in the incidence of PCI complications. We observed a lower usage of clopidogrel, GP IIb/IIIa inhibitors and parenteral anticoagulant in UA group during hospitalization (for all p<0.0001). Ejection fraction LVEF was higher in UA group (56% vs. 54% p=0.0026) at discharge. The 30-day and 1 year prognosis in both group was low with no statistical difference (Table 1).
Table 1. Mortality rate in studied group NSTEMI group (N=580) UA group (N=563) P 30-day mortality 1.60% 0.70% 0.1799 6-month mortality 2.20% 0.90% 0.0662 One year mortality 3.10% 1.60% 0.0940

Conclusions
Clinical course of ACS in young women is different regardless of the type of ACS (NSTEMI/UA) however with no difference in mortality rate. Typical symptoms increases the probability of unstable angina (UA) 2.8 times (p=0.0003). In the UA group, ACS was rarely related to circumflex and diagonal branch with more frequent in-stent restenosis. PCI delay in patients with UA results from a longer door-to-ballon time.